0001209191-20-020507.txt : 20200320
0001209191-20-020507.hdr.sgml : 20200320
20200320174906
ACCESSION NUMBER: 0001209191-20-020507
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200318
FILED AS OF DATE: 20200320
DATE AS OF CHANGE: 20200320
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hoerter Steven L.
CENTRAL INDEX KEY: 0001533451
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38219
FILM NUMBER: 20733077
MAIL ADDRESS:
STREET 1: 2525 28TH STREET, SUITE 100
CITY: BOULDER
STATE: CO
ZIP: 80301
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Deciphera Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001654151
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 200299725
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 SMITH STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 781-209-6400
MAIL ADDRESS:
STREET 1: 200 SMITH STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
FORMER COMPANY:
FORMER CONFORMED NAME: Deciphera Pharmaceuticals, LLC
DATE OF NAME CHANGE: 20150928
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-03-18
0
0001654151
Deciphera Pharmaceuticals, Inc.
DCPH
0001533451
Hoerter Steven L.
C/O DECIPHERA PHARMACEUTICALS, INC.
200 SMITH STREET
WALTHAM
MA
02451
1
1
0
0
President and CEO
Common Stock
2020-03-18
4
M
0
2250
25.40
A
54250
D
Common Stock
2020-03-19
4
F
0
4494
35.78
D
49756
D
Common Stock
2020-03-19
4
F
0
1012
36.88
D
48744
D
Common Stock
2020-03-19
4
F
0
4230
38.26
D
44514
D
Common Stock
2020-03-19
4
F
0
2164
39.22
D
42350
D
Common Stock
2020-03-19
4
F
0
520
39.98
D
41830
D
Stock Option (Right to Buy)
25.40
2019-03-18
4
A
0
2250
0.00
D
2029-03-17
Common Stock
2250
397750
D
On March 18, 2019 the Reporting Person was granted 22,000 Restricted Stock Units (RSUs) which vested in full on March 18, 2020 and was granted 30,000 RSUs which vest in four (4) equal annual installments beginning on March 18, 2020. These RSUs were reported in Table I on a Form 4 filed on March 20, 2019. The sale of shares reported in this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to cover tax obligations.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.27 to $36.01, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.73 to $37.24, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.77 to $38.76, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.79 to $39.77, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.88 to $40.01, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. 25% of the options shall vest on March 18, 2020, and the remaining options shall vest in equal monthly installments over the following three years, subject to continued service through such dates.
/s/ Jeffrey Held, Attorney-in-Fact
2020-03-20